Efficacy

Efficacy of Rybrevant (amivantamab-vmjw) in Lung Cancer

Rybrevant (amivantamab-vmjw) is a bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. This approval is based on the results of the clinical trial CHRYSALIS, which demonstrated the efficacy of Rybrevant in this patient population. In the trial, Rybrevant showed a significant response rate in patients with EGFR exon 20 insertion-positive NSCLC, indicating its potential as a targeted therapy for this subset of lung cancer patients.

The CHRYSALIS trial reported an objective response rate (ORR) of approximately 40% in patients treated with Rybrevant, with a median duration of response (DoR) of around 11 months. This suggests that Rybrevant can induce a meaningful tumor shrinkage in a considerable proportion of treated patients. Moreover, the median progression-free survival (PFS) was observed to be around 8.3 months, which is notable for patients with EGFR exon 20 insertion mutations who have limited treatment options after first-line therapy.

Efficacy of Augtyro (repotrectinib) in Lung Cancer

Augtyro (repotrectinib) is an investigational, next-generation tyrosine kinase inhibitor (TKI) targeting the tropomyosin receptor kinase (TRK), ROS1, and anaplastic lymphoma kinase (ALK) that is being studied for the treatment of patients with advanced NSCLC harboring ROS1 or NTRK fusions. While Augtyro is not yet approved by the FDA, clinical trials have been conducted to evaluate its efficacy in lung cancer patients with these genetic alterations. The preliminary data from these trials suggest that Augtyro has the potential to be an effective treatment option for patients with NSCLC carrying specific oncogenic drivers.

In early clinical trial results, Augtyro has demonstrated promising antitumor activity with a favorable safety profile in NSCLC patients with ROS1 or NTRK fusions. The ORR for patients with ROS1-positive NSCLC was reported to be high, with durable responses. The data also indicates that Augtyro has intracranial activity, which is particularly important for lung cancer patients who often experience brain metastases. The detailed efficacy data, including ORR, DoR, and PFS, will be crucial in determining Augtyro's role in the treatment landscape for lung cancer and are eagerly awaited by the medical community.